ASCO - American Society of Clinical Oncology

02/11/2019 | Press release | Distributed by Public on 02/11/2019 22:18

Phase II Trial Shows Novel, Radiolabeled PSMA-Targeted Treatment Provides High Response Rates in Men With Metastatic Prostate Cancer